Second Edition
AIDS Medicines and diagnostics services
July 2015
Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018. World Health Organization.
Module 4
Leaders
July 2017
Module 4: Leaders. This module aims to inform and update leaders and decision-makers about PrEP. It provides information on the benefits and limitations of PrEP so that they can consider how PrEP could be effectively implemented in their own settings. It also contai...ns a series of frequently asked questions about PrEP.
more
Sepsis contributes significantly to preventable mortality and is the final common pathway to death for severe infectious diseases; it can also arise as a complication of injuries and non-communicable diseases.
Ebola Virus Disease Outbreak Response Plan in West Africa July to December 2014 Annex 4
Bulletin of the World Health Organization 2007;85:637–643
Une traduction en français de ce résumé figure à la fin de l’article.
Al final del artículo se facilita una traducción al español.
الترجمة العربية لهذه الخلاصة في نهاية النص الكامل ل...هذه المقالة.
more
Many of the countries in the European Region receiving refugees from Ukraine are already offering vaccination services to children and adults. This is important to mitigate the risk of COVID-19 transmission among people travelling or living in close quarters, to protect the refugees from diseases th...at may be circulating in the host country, and prevent any outbreaks of vaccine-preventable diseases such as measles and polio.
more
Lateral-flow rapid diagnostic tests (RDTs) continue to play a vital role in global health in the management and diagnosis of infectious diseases, including malaria, HIV and COVID-19. Visually interpreted RDTs, more than any other class of diagnostics, fulfil WHO’s ASSURED criteria,1 enabling their... use at the lowest levels of health care and in self-testing.2 Their utility is, however, compromised every time a test is incorrectly performed or interpreted or its result is not available in a timely manner for clinical decisionmaking and surveillance.
more
Fact Book on WHO Level I and Level II monitoring indicators - To monitor the progress of efforts to improve the global medicines situation, WHO has developed a system of indicators that measure important aspects of a country’s pharmaceutical situation. Level 1 indicators measure the existence and ...performance of key national pharmaceutical structures and processes. Level II indicators measure key outcomes of these structures and processes in the areas of access, product quality and rational use. These indicators can be used to assess progress over time; to compare situations between countries; and to reassess and prioritize efforts based on the results.
This Fact Book gives the results of the assessment of Level I indicators conducted in 2003 and of Level II indicator surveys conducted between 2002 and 2004
more
Guidelines
Key Populations
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...rmulations on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
This report compiles data for the first time on the far-reaching consequences of uncontrolled hypertension, including heart attacks, strokes and premature death, along with substantial economic losses for communities and countries. It also contains information on the global, regional and country-lev...el burden of hypertension and progress of control efforts.
more
IPCAT2 will assist countries to determine the core components already in place, that is, existing strengths, and to identify gaps or weaknesses to guide action planning. IPCAT2 corresponds to the six core component recommendations of the guidelines targeted at the national level.
It is very impor...tant to understand that IPCAT2 is not intended to be used as an audit tool. Its purpose is to help assess, plan, organize and implement a national IPC programme. The tool provides a general overview of the status of IPC activities according to the guideline recommendations, rather than focusing on specific IPC practices/risk factors related to individual patients or specific.
more
Treat 3 Million by 2005
WHO/HIV/2005.02
African Region